FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4360992337> ?p ?o ?g. }

• W4360992337 endingPage "2170" @default.
• W4360992337 startingPage "2159" @default.
• W4360992337 abstract "Standard first-line chemotherapy for endometrial cancer is paclitaxel plus carboplatin. The benefit of adding pembrolizumab to chemotherapy remains unclear.In this double-blind, placebo-controlled, randomized, phase 3 trial, we assigned 816 patients with measurable disease (stage III or IVA) or stage IVB or recurrent endometrial cancer in a 1:1 ratio to receive pembrolizumab or placebo along with combination therapy with paclitaxel plus carboplatin. The administration of pembrolizumab or placebo was planned in 6 cycles every 3 weeks, followed by up to 14 maintenance cycles every 6 weeks. The patients were stratified into two cohorts according to whether they had mismatch repair-deficient (dMMR) or mismatch repair-proficient (pMMR) disease. Previous adjuvant chemotherapy was permitted if the treatment-free interval was at least 12 months. The primary outcome was progression-free survival in the two cohorts. Interim analyses were scheduled to be triggered after the occurrence of at least 84 events of death or progression in the dMMR cohort and at least 196 events in the pMMR cohort.In the 12-month analysis, Kaplan-Meier estimates of progression-free survival in the dMMR cohort were 74% in the pembrolizumab group and 38% in the placebo group (hazard ratio for progression or death, 0.30; 95% confidence interval [CI], 0.19 to 0.48; P<0.001), a 70% difference in relative risk. In the pMMR cohort, median progression-free survival was 13.1 months with pembrolizumab and 8.7 months with placebo (hazard ratio, 0.54; 95% CI, 0.41 to 0.71; P<0.001). Adverse events were as expected for pembrolizumab and combination chemotherapy.In patients with advanced or recurrent endometrial cancer, the addition of pembrolizumab to standard chemotherapy resulted in significantly longer progression-free survival than with chemotherapy alone. (Funded by the National Cancer Institute and others; NRG-GY018 ClinicalTrials.gov number, NCT03914612.)." @default.
• W4360992337 created "2023-03-30" @default.
• W4360992337 creator A5001069897 @default.
• W4360992337 creator A5001173182 @default.
• W4360992337 creator A5003854163 @default.
• W4360992337 creator A5006402876 @default.
• W4360992337 creator A5006618032 @default.
• W4360992337 creator A5009967316 @default.
• W4360992337 creator A5024497385 @default.
• W4360992337 creator A5042137756 @default.
• W4360992337 creator A5048917713 @default.
• W4360992337 creator A5049857815 @default.
• W4360992337 creator A5050465341 @default.
• W4360992337 creator A5052236281 @default.
• W4360992337 creator A5053852463 @default.
• W4360992337 creator A5054602117 @default.
• W4360992337 creator A5055824335 @default.
• W4360992337 creator A5056126942 @default.
• W4360992337 creator A5056321055 @default.
• W4360992337 creator A5058330531 @default.
• W4360992337 creator A5061736280 @default.
• W4360992337 creator A5062252471 @default.
• W4360992337 creator A5064454878 @default.
• W4360992337 creator A5068446974 @default.
• W4360992337 creator A5069651655 @default.
• W4360992337 creator A5072447565 @default.
• W4360992337 creator A5083622818 @default.
• W4360992337 creator A5088826153 @default.
• W4360992337 creator A5089453381 @default.
• W4360992337 date "2023-06-08" @default.
• W4360992337 modified "2023-10-17" @default.
• W4360992337 title "Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer" @default.
• W4360992337 cites W1940241680 @default.
• W4360992337 cites W1990639292 @default.
• W4360992337 cites W2008534009 @default.
• W4360992337 cites W2016471508 @default.
• W4360992337 cites W2019607817 @default.
• W4360992337 cites W2032075167 @default.
• W4360992337 cites W2033708244 @default.
• W4360992337 cites W2034751554 @default.
• W4360992337 cites W2041440766 @default.
• W4360992337 cites W2059707463 @default.
• W4360992337 cites W2149564130 @default.
• W4360992337 cites W2432531102 @default.
• W4360992337 cites W2518381736 @default.
• W4360992337 cites W2612419201 @default.
• W4360992337 cites W2625023228 @default.
• W4360992337 cites W2796582438 @default.
• W4360992337 cites W2923110060 @default.
• W4360992337 cites W2945254664 @default.
• W4360992337 cites W2947309006 @default.
• W4360992337 cites W2970410478 @default.
• W4360992337 cites W2984359187 @default.
• W4360992337 cites W2986633517 @default.
• W4360992337 cites W3011919019 @default.
• W4360992337 cites W3090741377 @default.
• W4360992337 cites W3093220519 @default.
• W4360992337 cites W4206041598 @default.
• W4360992337 cites W4206897023 @default.
• W4360992337 cites W4226407945 @default.
• W4360992337 cites W4229030847 @default.
• W4360992337 cites W4315754639 @default.
• W4360992337 doi "https://doi.org/10.1056/nejmoa2302312" @default.
• W4360992337 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36972022" @default.
• W4360992337 hasPublicationYear "2023" @default.
• W4360992337 type Work @default.
• W4360992337 citedByCount "41" @default.
• W4360992337 countsByYear W43609923372023 @default.
• W4360992337 crossrefType "journal-article" @default.
• W4360992337 hasAuthorship W4360992337A5001069897 @default.
• W4360992337 hasAuthorship W4360992337A5001173182 @default.
• W4360992337 hasAuthorship W4360992337A5003854163 @default.
• W4360992337 hasAuthorship W4360992337A5006402876 @default.
• W4360992337 hasAuthorship W4360992337A5006618032 @default.
• W4360992337 hasAuthorship W4360992337A5009967316 @default.
• W4360992337 hasAuthorship W4360992337A5024497385 @default.
• W4360992337 hasAuthorship W4360992337A5042137756 @default.
• W4360992337 hasAuthorship W4360992337A5048917713 @default.
• W4360992337 hasAuthorship W4360992337A5049857815 @default.
• W4360992337 hasAuthorship W4360992337A5050465341 @default.
• W4360992337 hasAuthorship W4360992337A5052236281 @default.
• W4360992337 hasAuthorship W4360992337A5053852463 @default.
• W4360992337 hasAuthorship W4360992337A5054602117 @default.
• W4360992337 hasAuthorship W4360992337A5055824335 @default.
• W4360992337 hasAuthorship W4360992337A5056126942 @default.
• W4360992337 hasAuthorship W4360992337A5056321055 @default.
• W4360992337 hasAuthorship W4360992337A5058330531 @default.
• W4360992337 hasAuthorship W4360992337A5061736280 @default.
• W4360992337 hasAuthorship W4360992337A5062252471 @default.
• W4360992337 hasAuthorship W4360992337A5064454878 @default.
• W4360992337 hasAuthorship W4360992337A5068446974 @default.
• W4360992337 hasAuthorship W4360992337A5069651655 @default.
• W4360992337 hasAuthorship W4360992337A5072447565 @default.
• W4360992337 hasAuthorship W4360992337A5083622818 @default.
• W4360992337 hasAuthorship W4360992337A5088826153 @default.
• W4360992337 hasAuthorship W4360992337A5089453381 @default.
• W4360992337 hasConcept C121608353 @default.
• W4360992337 hasConcept C126322002 @default.

• next